Meeting Banner
Abstract #2924

In Vivo 3T Clinical Magnetic Resonance Imaging with a Biologically Specific Contrast Agent in Prostate Cancer: A Nude Mouse Model

Christopher Brian Abraham1,2, Prashant Jani3, Roxanne Turuba1,2, Michael Campbell1,2, Ingeborg Zehbe1,2, and Laura Curiel1,2

1Lakehead University, Thunder Bay, ON, Canada, 2Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada, 3Thunder Bay Regional Health Science Center, Thunder Bay, ON, Canada

In this study we characterized in vivo a functional superparagmagnetic iron-oxide magnetic resonance contrast agent that effects the T2 relaxation time in MRI. The agent was developed by conjugating Molday Ion Carboxyl-6 (MIC6), with a de-immunized mouse monoclonal antibody (muJ591) targeting prostate-specific membrane antigen (PSMA). We propose this functional contrast agent as a non-invasive method to detect prostate cancer cells that are PSMA positive to provide increased differentiability from surrounding tissues for treatment. PSMA-positive prostate tumours were induced into 20 immunocompromised mice. The functional contrast agent was injected into 14 mice leaving 6 mice as controls. MR imaging was performed on a clinical 3T scanner using different parameters on a MESE sequence to obtain T2 relaxation time values. Tumour size, signal intensity, and T2 relaxation time were obtained pre and post injection and were found to have a lower value for treated mice compared to controls. ICP confirmed the increased level of elemental iron in treated mice tumours compared to controls. H&E staining showed healthy morphology of all tissues collected. The reduction in T2 relaxation time for the functional contrast agent, combined with its specificity against PSMA suggest its potential as a biologically-specific MR contrast agent.

This abstract and the presentation materials are available to members only; a login is required.

Join Here